Denmark's medical cannabis pilot showed both potential benefits and potential harms

Medical cannabis users scored higher on treatment satisfaction (29.2 vs. 26.5, p=0.006) and lower on depression (3.3 vs. 4.6, p=0.03) compared to propensity-matched controls. However, users reported higher pain levels on the SF-36 bodily pain subdomain (36.3 vs. 48.7, p=0.01, lower = more pain). There were indications of worse MS symptoms in cannabis users. Side effects were generally mild.

Cross-sectional study within Denmark's medical cannabis pilot program (launched January 2018). Cases who redeemed MC/CBM prescriptions were propensity-score matched to controls with same indications. Both groups completed online surveys and in-person interviews assessing depression, anxiety, cognition, satisfaction, and pain.

Denmark's pilot program provides a rare national-level experiment in medical cannabis. The mixed results (better satisfaction and depression, worse pain scores) illustrate the complexity of evaluating medical cannabis and the danger of focusing on only positive or only negative outcomes.

The paradox of higher satisfaction but worse pain scores could mean that medical cannabis improves aspects of well-being (mood, coping) without necessarily reducing pain itself. Alternatively, the higher pain scores may reflect confounding by indication: patients with worse pain may be more likely to seek cannabis treatment.

Cross-sectional design cannot determine causation. Propensity matching cannot eliminate all confounders. Self-selection into the pilot program introduces bias. Higher pain in the cannabis group may reflect worse baseline conditions.